|1.||de Dávila, María Teresa G: 3 articles (06/2015 - 01/2010)|
|2.||Camarero, Sandra: 3 articles (06/2015 - 01/2010)|
|3.||Chantada, Guillermo: 2 articles (06/2015 - 01/2011)|
|4.||McCarthy, Keith: 2 articles (05/2014 - 01/2012)|
|5.||Morland, Bruce: 2 articles (05/2014 - 01/2012)|
|6.||Shankar, Ananth: 2 articles (05/2014 - 01/2012)|
|7.||Hewitt, Martin: 2 articles (05/2014 - 01/2012)|
|8.||Hayward, Janis: 2 articles (05/2014 - 01/2012)|
|9.||Gabri, Mariano R: 2 articles (01/2011 - 01/2010)|
|10.||Galluzzo, Laura: 2 articles (01/2011 - 01/2010)|
01/01/2011 - "Presence of NeuGc-GM3 was evident in 23 of 27 cases (85%), with an average of about 70% of positive tumors cells. "
05/01/2004 - "Analysis of the ganglioside components using mAbs indicated that NeuAc-NeuGc-type GD2 was generated in the xenogeneic tumors by incorporating NeuGc-GM3 from mouse blood. "
01/01/2010 - "The present study evidenced the expression of NeuGc-GM3 in a high proportion of Wilms tumors, suggesting its potential utility as a specific target of immunotherapy."
01/01/2011 - "No significant differences were observed between neuroblastoma with and without NMYC oncogene amplification, suggesting that expression of NeuGc-GM3 is preserved in more aggressive cancers. "
10/01/2009 - "Here, we report the crystal structure of the chP3 Fab and its computer-docking model with the trisaccharide NeuGcalpha3Galbeta4Glcbeta, which represents the carbohydrate moiety of the tumor-antigen NeuGc-GM3. "
01/01/2010 - "The N-glycolylated ganglioside NeuGc-GM3 has been described in some neoplasms, such as breast carcinoma and melanoma, but is usually not detected in normal human cells. "
01/01/2011 - "The N-glycolylated ganglioside NeuGc-GM3 has been described in solid tumors such as breast carcinoma, nonsmall cell lung cancer, and melanoma, but is usually not detected in normal human cells. "
05/01/1996 - "Thus, expression of elevated levels of PKC-beta 1 and PKC-beta 2 in differentiated HD3 colon carcinoma cells blocked their differentiation, enabled them to proliferate in response to basic FGF like undifferentiated cells, increased their growth rate in athymic mice, and activated several MBP kinases, among them, p57 MAP kinase."
03/01/1994 - "Two of these colon carcinoma cell lines, U9 and HD3, which activate approximately equal amounts of TGF-beta 1 and express equal amounts of TGF-beta receptors, are now used to compare the effects of TGF-beta 1 in modulating invasive behavior. "
09/01/1994 - "In this report, we have examined the role of nm23 in two HT29 colon carcinoma sublines at different stages in tumor progression with different responses to TGF beta 1: the HD3 subline, which shows TGF beta 1-induced growth arrest and differentiation; and the more invasive and tumorigenic U9 subline, which induces tumors 7-fold as large as those induced by HD3 cells with one-half the latency. "
|3.||Hodgkin Disease (Hodgkin's Disease)
05/01/2014 - "Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy."
02/01/1988 - "Between July 1983 and May 1987 143 untreated patients with Hodgkin's lymphoma in stages I-IIIA with risk factors qualified for the HD1 protocol, and 230 patients in stages IIIB/IV qualified for HD3. "
04/01/1987 - "Between July 1983 and September 1986 358 untreated patients with Hodgkin's lymphoma qualified for the protocols HD1 (stages I to IIIA with risk factors), HD2 (stage IIIA), and HD3 (stages IIIB and IVAB). "
06/01/1986 - "Between July 1982 and June 1985 235 out of 436 untreated patients with Morbus Hodgkin's disease qualified for the protocols HD1 (stage IA to IIIA with risk factors), HD2 (stage IIIA) and HD3 (stages IIIB and IVA/B). "
01/01/2012 - "Clinical outcome in children and adolescents with Hodgkin lymphoma after treatment with chemotherapy alone - the results of the United Kingdom HD3 national cohort trial."
|4.||Neuroectodermal Tumors (Neuroectodermal Tumor)
01/01/2011 - "Our aim was to evaluate the presence of NeuGc-GM3 in pediatric neuroectodermal tumors by immunohistochemistry. "
01/01/2011 - "The present study evidenced the expression of NeuGc-GM3 in a high proportion of neuroectodermal tumors, suggesting its potential utility as a specific target of immunotherapy."
|5.||Chronic Kidney Failure (Chronic Renal Failure)
10/01/2015 - "The study was performed in 47 end stage renal disease (ESRD) patients, subdivided into four groups: 19 patients within the first 6 months from starting HD therapy (HD1); the same patients studied 18 ± 3 months later (HD2); patients with no history of AF and long dialytic age (HD3, n = 13); and patients with sinus rhythm but history of AF (HDAF, n = 15); and 18 healthy controls. "
|1.||Transforming Growth Factor beta1 (TGF beta 1)
|2.||Transforming Growth Factor beta (TGF-beta)
|3.||Messenger RNA (mRNA)
|8.||Butyric Acid (Butanoic Acid)
|2.||Drug Therapy (Chemotherapy)